Perhaps you should do a bit of due dillengence on the subject. MF has a large client base that includes private and commerical investors. Motley Fool produces a yearly list of promising drug candiates within the immuno arena and MK did not make the list for 2016 meaning share value is affected. However it is not just MF not one biotech investment advisor has listed MK as a game changer. MK is not even known within the medical trial community..Think I am wrong? Ask you doctor or dentist? Ask you broker for it's opinion.....We are deep in P-3 and still in a struggle to exist with not one take over candiate making thier interest known, not one leak from those in the trial and not one
family office or brokerage firm interested in a take over or merger as Geert predicted when P-3 was approved.